NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement equity grants for five non-executive new hires on May 1, 2026. The Compensation Committee approved 50,400 share options (exercise price $28.43) and 15,400 restricted stock units.
Options vest over four years (25% at one year then 36 monthly installments). RSUs vest over three years (one-third each year). Grants issued under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – NAMS
On the day this news was published, NAMS gained 5.03%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Among close biotech peers, moves were mixed: MLYS +5.44%, CRNX +0.42%, while VKTX -4.15%, RARE -0.52%, APLS -0.01%. With only one momentum peer flagged and no consistent direction, NAMS’s action looks stock-specific rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Conference appearance | Neutral | +0.3% | Needham virtual healthcare conference fireside chat announcement and webcast details. |
| Apr 02 | Inducement grants | Neutral | +3.4% | Inducement options and RSUs for two non-executive hires under 2024 plan. |
| Mar 23 | Scientific presentations | Positive | +3.7% | ACC.26 posters on obicetrapib kidney outcomes, safety, and LDL-CVD risk data. |
| Mar 06 | Inducement grants | Neutral | +3.0% | Equity inducement awards to two hires with multi-year vesting schedules. |
| Feb 25 | Investor conferences | Neutral | -2.8% | Planned participation in multiple March investor conferences and webcasts. |
Recent "news"-tag items (inducement grants, conference participation) have often coincided with modest positive moves, suggesting the stock has reacted constructively to routine corporate updates.
Over the last few months, NAMS news flow has centered on conferences and equity incentives. Inducement grant announcements on Mar 2, 2026 and Apr 1, 2026 under the 2024 Inducement Plan drew modest gains of 3.05% and 3.43%. Scientific visibility increased with three ACC.26 presentations announced on Mar 23, 2026, associated with a 3.7% move. Conference participation and corporate outreach (Needham, March investor events) round out a pattern of steady, non-transformational updates similar in tone to today’s inducement awards.
Market Pulse Summary
The stock moved +5.0% in the session following this news. A strong positive reaction aligns with prior responses to similar equity grant announcements, which previously accompanied 3–4% moves on routine inducement news. While the awards add incremental share-based compensation over time, they also reflect ongoing hiring to support late-stage programs. Investors would watch how repeated equity incentives, insider selling activity, and conference or clinical updates interact to determine whether enthusiasm proves durable.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
AI-generated analysis. Not financial advice.
NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 15,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units were granted on May 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
